Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 83

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---

Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level
3 of the fair value hierarchy at the measurement date due to the use of unobservable inputs inherent in pricing models are assumptions
related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary
share based on historical volatility that matches the expected remaining life of the option. The risk-free interest rate is based on
the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the option. The
expected life of the option is assumed to be equivalent to their remaining contractual term.

The
rights were valued using an iterative analysis based on market comparable. The following criteria was utilized to select comparable Special
Purpose Acquisition Companies who were pre-business combination and included rights as part of their units that were publicly trading
with significant time remaining to complete their initial business combination:

    Criteria 
    Low  
    High 
  
    IPO Proceeds 
     60  
     250 
  
    Warrant Coverage 
     -  
     0.5 
  
    Rights Coverage (per unit) 
     0.05  
     0.13 
  
    Remaining Months to Complete 
     7  
     21 

17

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

NOTE 9
— SEGMENT INFORMATION

ASC
Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information
about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components
of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating
decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

The
Company’s CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole
to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company
only has one operating segment.

The
CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported
on the unaudited statement of operations as